Merck & Company Inc (MRK)vsNuwellis Inc (NUWE)
MRK
Merck & Company Inc
$130.40
-0.44%
HEALTHCARE · Cap: $307.25B
NUWE
Nuwellis Inc
$1.89
-2.07%
HEALTHCARE · Cap: $177,950
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 749906% more annual revenue ($65.77B vs $8.77M). MRK leads profitability with a 13.6% profit margin vs -217.2%. NUWE trades at a lower P/E of 0.0x. MRK earns a higher WallStSmart Score of 50/100 (D+).
MRK
Hold50
out of 100
Grade: D+
NUWE
Hold37
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-62.3%
Fair Value
$81.23
Current Price
$130.40
$49.17 premium
Intrinsic value data unavailable for NUWE.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Strong operational efficiency at 38.6%
Generating 2.9B in free cash flow
Attractively priced relative to earnings
Reasonable price relative to book value
Conservative balance sheet, low leverage
Revenue surging 26.2% year-over-year
Areas to Watch
Premium valuation, high expectations priced in
4.9% revenue growth
Elevated debt levels
Weak financial health signals
Smaller company, higher risk/reward
Weak financial health signals
ROE of -657.5% — below average capital efficiency
Earnings declined 99.2%
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.
Bull Case : NUWE
The strongest argument for NUWE centers on P/E Ratio, Price/Book, Debt/Equity. Revenue growth of 26.2% demonstrates continued momentum.
Bear Case : MRK
The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.
Bear Case : NUWE
The primary concerns for NUWE are Market Cap, Piotroski F-Score, Return on Equity.
Key Dynamics to Monitor
MRK profiles as a value stock while NUWE is a growth play — different risk/reward profiles.
NUWE carries more volatility with a beta of 0.30 — expect wider price swings.
NUWE is growing revenue faster at 26.2% — sustainability is the question.
MRK generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
MRK scores higher overall (50/100 vs 37/100). Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Nuwellis Inc
HEALTHCARE · MEDICAL DEVICES · USA
Nuwellis, Inc., a medical device company, focuses on the development, manufacture and marketing of medical devices used in ultrafiltration therapy. The company is headquartered in Eden Prairie, Minnesota.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?